SCHEMBL1671808

SCHEMBL1671808

CC(C)CNCCn1c(Sc2cc3c(cc2I)SCC3)nc2c(N)ncnc21

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 10/20 0.66
HSP90AB1 P08238 10/20 0.53
HSP90AA1 P07900 9/20 0.53
TRAP1 Q12931 4/20 0.53
HSP90B1 P14625 3/20 0.53
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1669187 0.97 ERBB2 (0.64) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL1669380 0.88 HSP90AA1 (0.69) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL1669699 0.87 ERBB2 (0.69) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL18203383 0.87 ERBB2 (0.69) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL18203343 0.87 HSP90AB1 (0.51) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL11903640 0.85 HSP90AB1 (0.54) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL11908978 0.85 HSP90AB1 (0.67) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL1669202 0.85 HSP90AA1 (0.69) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL1669151 0.84 ERBB2 (0.64) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1
SCHEMBL11908887 0.84 ERBB2 (0.64) ERBB2HSP90AB1HSP90AA1TRAP1HSP90B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3091019-B1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS SLOAN KETTERING INST CANCER RES (US) 2019-04-03 EP disclosed
US-10172863-B2 Purine derivatives useful as HSP90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2019-01-08 US disclosed
EP-3091019-A2 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS Sloan Kettering Institute For Cancer Research (US) 2016-11-09 EP disclosed
US-20160310497-A1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2016-10-27 US disclosed
US-9328114-B2 Hsp90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2016-05-03 US disclosed
US-20120208806-A1 Hsp90 Inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-08-16 US disclosed
EP-2486039-A1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS Sloan Kettering Institute For Cancer Research (US) 2012-08-15 EP disclosed
WO-2011044394-A1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172863-B2 Purine derivatives useful as HSP90 inhibitors XDH, HSP90B1, HSP90AA1 ERBB2 4122/4885HSP90AB1 4/4885HSP90AA1 3/4885
US-20120208806-A1 Hsp90 Inhibitors HSP90B1, HSP90AB1, HSP90AB2P ERBB2 2315/4885HSP90AB1 2/4885HSP90AA1 4/4885
US-20160310497-A1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS XDH, HSP90B1, HSP90AA1 ERBB2 4122/4885HSP90AB1 4/4885HSP90AA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.